Monthly Archives: August 2015

Proton Pump Inhibitors and Myocardial Infarction: the Current Perspective

Posted in News | Comments Off on Proton Pump Inhibitors and Myocardial Infarction: the Current Perspective

Functional brain imaging reveals rapid blockade of abdominal pain response upon anti-TNF therapy in Crohn’s disease

Posted in News | Comments Off on Functional brain imaging reveals rapid blockade of abdominal pain response upon anti-TNF therapy in Crohn’s disease

Functional brain imaging reveals rapid blockade of abdominal pain response upon anti-TNF therapy in Crohn’s disease

Posted in News | Comments Off on Functional brain imaging reveals rapid blockade of abdominal pain response upon anti-TNF therapy in Crohn’s disease

Identification of GLI Mutations in Patients with Hirschsprung Disease That Disrupt Enteric Nervous System Development in Mice

Hirschsprung disease is characterized by a deficit in enteric neurons, which are derived from neural crest cells (NCCs). Aberrant hedgehog signaling disrupts NCC differentiation and might cause Hirschsprung disease. We performed genetic analyses to det… Continue reading

Posted in News | Comments Off on Identification of GLI Mutations in Patients with Hirschsprung Disease That Disrupt Enteric Nervous System Development in Mice

Identification of GLI Mutations in Patients with Hirschsprung Disease That Disrupt Enteric Nervous System Development in Mice

Hirschsprung disease is characterized by a deficit in enteric neurons, which are derived from neural crest cells (NCCs). Aberrant hedgehog signaling disrupts NCC differentiation and might cause Hirschsprung disease. We performed genetic analyses to det… Continue reading

Posted in News | Comments Off on Identification of GLI Mutations in Patients with Hirschsprung Disease That Disrupt Enteric Nervous System Development in Mice

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

Approaches to risk stratification for patients with primary biliary cirrhosis (PBC) are limited, single-center based, and often dichotomous. We aimed to develop and validate a better model for determining prognoses of patients with PBC. Continue reading

Posted in News | Comments Off on Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

Approaches to risk stratification for patients with primary biliary cirrhosis (PBC) are limited, single-center based, and often dichotomous. We aimed to develop and validate a better model for determining prognoses of patients with PBC. Continue reading

Posted in News | Comments Off on Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

Increased Expression of DUOX2 is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine

Dual oxidase 2 (DUOX2), a hydrogen-peroxide generator at the apical membrane of gastrointestinal epithelia, is upregulated in patients with inflammatory bowel disease (IBD) before the onset of inflammation, but little is known about its effects. We inv… Continue reading

Posted in News | Comments Off on Increased Expression of DUOX2 is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine

Increased Expression of DUOX2 is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine

Dual oxidase 2 (DUOX2), a hydrogen-peroxide generator at the apical membrane of gastrointestinal epithelia, is upregulated in patients with inflammatory bowel disease (IBD) before the onset of inflammation, but little is known about its effects. We inv… Continue reading

Posted in News | Comments Off on Increased Expression of DUOX2 is an Epithelial Response to Mucosal Dysbiosis Required for Immune Homeostasis in Mouse Intestine

Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection

We performed a phase 2 clinical trial to evaluate the efficacy and safety of ledipasvir and sofosbuvir, with or without ribavirin, in patients infected with HCV genotype 3 or 6. Continue reading

Posted in News | Comments Off on Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection